Robert Linton Reeves Munden
CIK 1488578 · View on SEC EDGAR ↗
First SEC filing: April 17, 2014 · Latest: April 17, 2014
On this page
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
No open-market trades on record; showing all filings.
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| June 23, 2017 | HHS | A | 232,394 | — | — | 232,394 Direct | — | Acquired | (price as of 2026-08-21) |
| June 23, 2017 | HHS | A | 154,929 | — | — | 154,929 Direct | — | Acquired | (price as of 2026-08-21) |
| April 15, 2017 | HHS | F | 9,459 | $1.28 | $12,108 | 105,768 Direct | -8.21% | Disposed | -72.5% (price as of 2026-08-21) |
| April 15, 2016 | HHS | A | 44,000 | — | — | 115,227 Direct | +61.77% | Acquired | (price as of 2026-08-21) |
| April 15, 2016 | HHS | F | 3,784 | $2.69 | $10,179 | 71,227 Direct | -5.04% | Disposed | -86.9% (price as of 2026-08-21) |
| Feb. 5, 2016 | HHS | F | 2,722 | $3.27 | $8,901 | 75,011 Direct | -3.50% | Disposed | -89.2% (price as of 2026-08-21) |
| April 15, 2015 | HHS | A | 47,921 | — | — | 47,921 Direct | — | Acquired | (price as of 2026-08-21) |
| April 15, 2015 | HHS | A | 23,188 | — | — | 77,733 Direct | +42.51% | Acquired | (price as of 2026-08-21) |
| April 15, 2015 | HHS | F | 1,739 | $7.68 | $13,356 | 54,545 Direct | -3.09% | Disposed | -95.4% (price as of 2026-08-21) |
| Feb. 5, 2015 | HHS | F | 4,027 | $7.76 | $31,250 | 56,284 Direct | -6.68% | Disposed | -95.5% (price as of 2026-08-21) |
| April 15, 2014 | HHS | A | 46,073 | — | — | 46,073 Direct | — | Acquired | (price as of 2026-08-21) |
| April 15, 2014 | HHS | A | 19,715 | — | — | 60,311 Direct | +48.56% | Acquired | (price as of 2026-08-21) |
| Feb. 5, 2014 | HHS | F | 5,116 | $7.01 | $35,863 | 40,596 Direct | -11.19% | Disposed | -95.0% (price as of 2026-08-21) |
| Feb. 5, 2013 | HHS | A | 25,000 | — | — | 45,712 Direct | +120.70% | Acquired | (price as of 2026-08-21) |
| Feb. 5, 2013 | HHS | F | 2,458 | $7.72 | $18,976 | 20,712 Direct | -10.61% | Disposed | -95.4% (price as of 2026-08-21) |
| Sept. 18, 2012 | HHS | A | 60,000 | — | — | 60,000 Direct | -50.00% | Disposed | (price as of 2026-08-21) |
| Feb. 5, 2012 | HHS | A | 28,000 | — | — | 28,000 Direct | -50.00% | Disposed | (price as of 2026-08-21) |
| Feb. 5, 2012 | HHS | A | 192 | — | — | 23,170 Direct | +0.84% | Acquired | (price as of 2026-08-21) |
| Feb. 5, 2012 | HHS | A | 12,000 | — | — | 22,978 Direct | +109.31% | Acquired | (price as of 2026-08-21) |
| Feb. 5, 2012 | HHS | F | 1,022 | $9.91 | $10,128 | 10,978 Direct | -8.52% | Disposed | -96.4% (price as of 2026-08-21) |
| Feb. 5, 2011 | HHS | A | 12,000 | — | — | 12,000 Direct | -50.00% | Disposed | (price as of 2026-08-21) |
| Feb. 5, 2011 | HHS | A | 10,000 | — | — | 12,000 Direct | +500.00% | Acquired | (price as of 2026-08-21) |
| April 9, 2010 | HHS | A | 40,000 | — | — | 40,000 Direct | -50.00% | Disposed | (price as of 2026-08-21) |
| April 9, 2010 | HHS | A | 2,000 | — | — | 2,000 Direct | — | Acquired | (price as of 2026-08-21) |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II)
Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| June 23, 2017 | HHS | Stock Appreciation Right | Common Stock (232,394) | $0.97 | — | 232,394 | Acquired |
| June 23, 2017 | HHS | Restricted Stock Units | Common Stock (154,929) | — | — | 154,929 | Acquired |
| April 15, 2015 | HHS | Common Stock (right to buy) | Common Stock (47,921) | $7.68 | April 15, 2025 | 47,921 | Acquired |
| April 15, 2014 | HHS | Stock Option (right to buy) | Common Stock (46,073) | $8.23 | April 15, 2024 | 46,073 | Acquired |
| Sept. 18, 2012 | HHS | Stock Option (right to buy) | Common Stock (60,000) | $7.25 | Sept. 18, 2022 | 60,000 | Disposed |
| Feb. 5, 2012 | HHS | Stock Option (right to buy) | Common Stock (28,000) | $9.91 | Feb. 5, 2022 | 28,000 | Disposed |
| Feb. 5, 2011 | HHS | Stock Option (right to buy) | Common Stock (12,000) | $12.31 | Feb. 5, 2021 | 12,000 | Disposed |
| April 9, 2010 | HHS | Stock Option (right to buy) | Common Stock (40,000) | $13.19 | April 7, 2020 | 40,000 | Disposed |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
HHS
GeneralCounsel andSecretary| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2011 | — | $382 | — | — | — | — | — | — |
| 2010 | $187,500 | — | $26,380 | $167,931 | $159,375 | $8,185 | $27,705 | $577,076 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.